Mutational spectrum of p53 mutations in primary breast and ovarian tumors

Critical Reviews in Oncology/Hematology

Volumn 52, Issue 2, 2004, Pages 103-116

  Feki, Anis ^a   Irminger Finger, Irmgard ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Apoptosis; Breast cancer; Chemosensitivity; Ovarian cancer; p53; Prognostic marker

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FERTILITY PROMOTING AGENT; FLUOROURACIL; HORMONE; METHOTREXATE; ORAL CONTRACEPTIVE AGENT; PACLITAXEL; PROTEIN P53; RECOMBINANT DNA; TAMOXIFEN; THYMIDINE KINASE;

APOPTOSIS; BLADDER CANCER; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL PROLIFERATION; CHEMOSENSITIVITY; CLINICAL TRIAL; COLON CANCER; DNA MICROARRAY; DNA REPAIR; EPITHELIUM CELL; ESOPHAGUS CANCER; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENE TRANSFER; GENETIC DAMAGE; GENETIC SCREENING; HEAD CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKEMIA; LUNG CANCER; LYMPHOMA; METASTASIS; NECK CANCER; NONHUMAN; ONCOGENE; OVARY CANCER; PREVALENCE; PROGNOSIS; PROSTATE CANCER; REGULATORY MECHANISM; REVIEW; SENESCENCE; SIDE EFFECT; STOMACH CANCER; TREATMENT FAILURE; TUMOR SUPPRESSOR GENE; UTERUS CANCER;

BREAST NEOPLASMS; FAMILY HEALTH; FEMALE; GENE FREQUENCY; HUMANS; MUTATION; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 7044224706     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2004.07.002     Document Type: Review

References (136)

1. M. Hollstein, D. Sidransky, B. Vogelstein, and C. Harris p53 mutations in human cancers Science 253 1991 49 53
2. R.J. Osborne, G.R. Merlo, and T. Mitsudomi Mutations in the p53 gene in primary human breast cancers Cancer Res. 51 1991 6194 6198
3. D.M. Eccles, L. Brett, and A. Lessells Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma Br J Cancer 65 1992 40 44
4. A.K. Godwin, L. Vanderveer, and D.C. Schultz A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1 Am J Hum Genet 55 1994 666 677
5. W.D. Foulkes, D.M. Black, G.W. Stamp, E. Solomon, and J. Trowsdale Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma Int J Cancer 54 1993 220 225
6. S. Benchimol, D. Pim, and L. Crawford Radioimmunoassay of the cellular protein p53 in mouse and human cell lines Embo J 1 1982 1055 1062
7. M.B. Kastan, O. Onyekwere, D. Sidransky, B. Vogelstein, and R.W. Craig Participation of p53 protein in the cellular response to DNA damage Cancer Res. 51 1991 6304 6311
8. E. Yonish-Rouach, D. Resnitzky, J. Lotem, L. Sachs, A. Kimchi, and M. Oren Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 Nature 352 1991 345 347
9. A.J. Levine p53, the cellular gatekeeper for growth and division Cell 88 1997 323 331
10. C. Prives Signaling to p53: breaking the MDM2-p53 circuit Cell 95 1998 5 8
11. B. Rovinski, and S. Benchimol Immortalization of rat embryo fibroblasts by the cellular p53 oncogene Oncogene 2 1988 445 452
12. J.R. Jenkins, K. Rudge, and G.A. Currie Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53 Nature 312 1984 651 654
13. C. Caron de Fromentel, F. Pakdel, A. Chapus, C. Baney, P. May, and T. Soussi Rainbow trout p53: cDNA cloning and biochemical characterization Gene 112 1992 241 245
14. T. Soussi, Y. Legros, R. Lubin, K. Ory, and B. Schlichtholz Multifactorial analysis of p53 alteration in human cancer: a review Int J Cancer 57 1994 1 9
15. M.S. Greenblatt, W.P. Bennett, M. Hollstein, and C.C. Harris Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis Cancer Res 54 1994 4855 4878
16. C. Beroud, and T. Soussi p53 gene mutation: software and database Nucl Acids Res. 26 1998 200 204
17. S.P. Dowell, P.O. Wilson, N.W. Derias, D.P. Lane, and P.A. Hall Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens Cancer Res 1994 54
18. G. Casey, M.E. Lopez, and J.C. Ramos DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies Oncogene 1996 13
19. A.D. Thor, D.H. Moore II., and S.M. Edgerton Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers J Natl Cancer Inst 84 1992 845 855
20. D.C. Allred, G.M. Clark, and R. Elledge Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer J Natl Cancer Inst 85 1993 200 206
21. K. Iwaya, H. Tsuda, and H. Hiraide Nuclear p53 immunoreaction associated with poor prognosis of breast cancer Jpn J Cancer Res 82 1991 835 840
22. J.L. Ostrowski, A. Sawan, and L. Henry p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study J Pathol 164 1991 75 81
23. A. Ioakim-Liossi, P. Karakitsos, and C. Markopoulos p53 protein expression and oestrogen and progesterone receptor status in invasive ductal breast carcinomas Cytopathology 12 2001 197 202
24. J. Isola, T. Visakorpi, K. Holli, and O.P. Kallioniemi Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients J Natl Cancer Inst 84 1992 1109 1114
25. G. Cattoretti, F. Rilke, S. Andreola, L. D'Amato, and D. Delia p53 expression in breast cancer Int J Cancer 41 1988 178 183
26. C. Charpin, B. DeVictor, and L. Andrac p53 quantitative immunocytochemical analysis in breast carcinomas Hum Pathol 26 1995 159 166
27. R. Mazars, L. Spinardi, M. BenCheikh, J. Simony-Lafontaine, P. Jeanteur, and C. Theillet p53 mutations occur in aggressive breast cancer Cancer Res 52 1992 3918 3923
28. D.M. Barnes, E.A. Dublin, C.J. Fisher, D.A. Levison, and R.R. Millis Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol 24 1993 469 476
29. D.C. Allred, R. Elledge, G.M. Clark, and S.A. Fuqua The p53 tumor-suppressor gene in human breast cancer Cancer Treat Res 71 1994 63 77
30. P.L. Fitzgibbons, D.L. Page, and D. Weaver Prognostic factors in breast cancer, College of American Pathologists Consensus Statement Arch Pathol Lab Med 124 2000 966 978
31. R.M. Elledge, and D.C. Allred Prognostic and predictive value of p53 and p21 in breast cancer Breast Cancer Res Treat 52 1998 79 98
32. S.W. Beenken, W.E. Grizzle, and D.R. Crowe Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53 Ann Surg 233 2001 630 638
33. P.P. Rosen, M.L. Lesser, C.D. Arroyo, M. Cranor, P. Borgen, and L. Norton p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis J Clin Oncol 13 1995 821 830
34. M.S. Greenblatt, P.O. Chappuis, J.P. Bond, N. Hamel, and W.D. Foulkes TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution Cancer Res. 61 2001 4092 4097
35. R. Silvestrini, E. Benini, and M.G. Daidone p53 as an independent prognostic marker in lymph node-negative breast cancer patients J Natl Cancer Inst 85 1993 965 970
36. E. Hanzal, G. Gitsch, P. Kohlberger, C. Dadak, N. Miechowiecka, and G. Breitenecker Immunohistochemical detection of mutant p53-suppressor gene product in patients with breast cancer: influence on metastasis-free survival Anticancer Res. 12 1992 2325 2329
37. T.I. Andersen, R. Holm, J.M. Nesland, K.R. Heimdal, L. Ottestad, and A.L. Borresen Prognostic significance of TP53 alterations in breast carcinoma Br J Cancer 68 1993 540 548
38. S. Thorlacius, A.L. Borresen, and J.E. Eyfjord Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor Cancer Res. 53 1993 1637 1641
39. E. Kucera, P. Speiser, and M. Gnant Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients, Austrian Breast Cancer Study Group Eur J Cancer 35 1999 398 405
40. J. Alsner, M. Yilmaz, P. Guldberg, L.L. Hansen, and J. Overgaard Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer Clin Cancer Res 6 2000 3923 3931
41. S. Geisler, P.E. Lonning, and T. Aas Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer Cancer Res 61 2001 2505 2512
42. R.M. Elledge, S.A. Fuqua, and G.M. Clark Prognostic significance of p53 gene alterations in node-negative breast cancer Breast Cancer Res Treat 26 1993 225 235
43. Y.H. Shiao, V.W. Chen, W.D. Scheer, X.C. Wu, and P. Correa Racial disparity in the association of p53 gene alterations with breast cancer survival Cancer Res 55 1995 1485 1490
44. E.M. Berns, J.G. Klijn, and W.L. van Putten p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer J Clin Oncol 16 1998 121 127
45. S. Lizard-Nacol, P. Genne, and B. Coudert MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients Anticancer Res. 19 1999 3575 3581
46. B. Powell, R. Soong, B. Iacopetta, R. Seshadri, and D.R. Smith Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer Clin Cancer Res 6 2000 443 451
47. Z.M. Shao, J. Wu, Z.Z. Shen, and M. Nguyen p53 mutation in plasma DNA and its prognostic value in breast cancer patients Clin Cancer Res 7 2001 2222 2227
48. J. Bergh, T. Norberg, S. Sjogren, A. Lindgren, and L. Holmberg Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy Nat Med 1995 1
49. N. Falette, M.P. Paperin, and I. Treilleux Prognostic value of p53 gene mutations in a large series of node-negative breast cancer patients Cancer Res 58 1998 1451 1455
50. M. Gentile, M. Bergman Jungestrom, K.E. Olsen, P. Soderkvist, and S. Wingren p53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation Eur J Cancer 35 1999 1202 1207
51. H. Blaszyk, A. Hartmann, and J.M. Cunningham A prospective trial of midwest breast cancer patients: a p53 gene mutation is the most important predictor of adverse outcome Int J Cancer 89 2000 32 38
52. M. Takahashi, H. Tonoki, and M. Tada Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers Int J Cancer 89 2000 92 99
53. A.P. Hoyer, A.M. Gerdes, T. Jorgensen, F. Rank, and H.B. Hartvig Organochlorines, p53 mutations in relation to breast cancer risk and survival. A Danish cohort-nested case-controls study Breast Cancer Res Treat 71 2002 59 65
54. M. Caleffi, M.W. Teague, R.A. Jensen, C.L. Vnencak-Jones, W.D. Dupont, and F.F. Parl p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment Cancer 73 1994 2147 2156
55. S. Chevillard, J. Lebeau, and P. Pouillart Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy Clin Cancer Res 3 1997 2471 2478
56. I.A. Olivotto, C.D. Bajdik, and I.H. Plenderleith Adjuvant systemic therapy and survival after breast cancer N Engl J Med 330 1994 805 810
57. C. Coles, A. Condie, U. Chetty, C.M. Steel, H.J. Evans, and J. Prosser p53 mutations in breast cancer Cancer Res 52 1992 5291 5298
58. A. Hamilton, and M. Piccart The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2 Ann Oncol 11 2000 647 663
59. P.C. Clahsen, C.J. van de Velde, and C. Duval p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer J Clin Oncol 16 1998 470 479
60. A. Makris, T.J. Powles, M. Dowsett, and C. Allred p53 protein overexpression and chemosensitivity in breast cancer Lancet 345 1995 1181 1182
61. S.C. Linn, H.M. Pinedo, and J. van Ark-Otte Expression of drug resistance proteins in breast cancer, in relation to chemotherapy Int J Cancer 71 1997 787 795
62. J. Jacquemier, F. Penault-Llorca, and P. Viens Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression Anticancer Res. 14 1994 2773 2778
63. A. Degeorges, A. de Roquancourt, and J.M. Extra Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer? Breast Cancer Res Treat 47 1998 47 55
64. R.M. Elledge, R. Gray, and E. Mansour Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer J Natl Cancer Inst 87 1995 1254 1256
65. M. Schuijer, and E.M. Berns TP53 and ovarian cancer Hum Mutat. 21 2003 285 291
66. Society, T.r.c.o.o.a.g.t.b.g.c. A joint working group response to "A policy framework for commissioning Cancer Services" consultation document.
67. S.H. Landis, T. Murray, S. Bolden, and P.A. Wingo Cancer statistics CA Cancer J Clin 49 31 1999 8 31
68. J.D. Woodruff History of ovarian neoplasia: facts and fancy Obstet Gynecol Annu 5 1976 331 344
69. R.E. Scully Ovarian tumors: a review Am J Pathol 87 1977 686 720
70. HK. Annual report on the results of treatment in gynecological cancer. Vol. 18. Stokholm: FIGO; 1982.
71. J.B.J. Chang, M. Gore, and C. Fisher Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group Bmj 303 1991 884 893
72. J.B.J. Chang, M. Gore, and C. Fisher Non-surgical aspects of ovarian cancer Lancet 343 1994 335 340
73. G. Saretzki, U. Hoffmann, and P. Rohlke Identification of allelic losses in benign, borderline, and invasive epithelial ovarian tumors and correlation with clinical outcome Cancer 80 1997 1241 1249
74. N. Phillips, M. Ziegler, B. Saha, and F. Xynos Allelic loss on chromosome 17 in human ovarian cancer Int J Cancer 54 1993 85 91
75. N.J. Phillips, M.R. Ziegler, and D.M. Radford Allelic deletion on chromosome 17p13.3 in early ovarian cancer Cancer Res 56 1996 606 611
76. N.J. Phillips, M.R. Zeigler, and L.L. Deaven A cDNA from the ovarian cancer critical region of deletion on chromosome 17p13.3 Cancer Lett 102 1996 85 90
77. S.J. Baker, A.C. Preisinger, and J.M. Jessup p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis Cancer Res. 50 1990 7717 7722
78. A. Berchuck, M.F. Kohler, and M.P. Hopkins Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors Gynecol Oncol 52 1994 232 236
79. A. Berchuck, M.F. Kohler, J.R. Marks, R. Wiseman, J. Boyd, and R.C. Bast Jr. The p53 tumor suppressor gene frequently is altered in gynecologic cancers Am J Obstet Gynecol 170 1994 246 252
80. R. Mazars, P. Pujol, T. Maudelonde, P. Jeanteur, and C. Theillet p53 mutations in ovarian cancer: a late event? Oncogene 6 1991 1685 1690
81. T. Kihana, H. Tsuda, S. Teshima, S. Okada, S. Matsuura, and S. Hirohashi High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy Jpn J Cancer Res 83 1992 978 984
82. B.J. Milner, L.A. Allan, and D.M. Eccles p53 mutation is a common genetic event in ovarian carcinoma Cancer Res 53 1993 2128 2132
83. M.F. Kohler, J.R. Marks, and R.W. Wiseman Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer J Natl Cancer Inst 85 1993 1513 1519
84. J. Kupryjanczyk, A.D. Thor, and R. Beauchamp p53 gene mutations and protein accumulation in human ovarian cancer Proc Natl Acad Sci USA 90 1993 4961 4965
85. I. Wertheim, M.G. Muto, W.R. Welch, D.A. Bell, R.S. Berkowitz, and S.C. Mok p53 gene mutation in human borderline epithelial ovarian tumors J Natl Cancer Inst 86 1994 1549 1551
86. J. Zheng, W.F. Benedict, and H.J. Xu Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas J Natl Cancer Inst 87 1995 1146 1153
87. S. Kappes, K. Milde-Langosch, and P. Kressin p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry Int J Cancer 64 1995 52 59
88. S.C. Righetti, G. Della Torre, and S. Pilotti A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma Cancer Res 56 1996 689 693
89. J.S. Skilling, A. Sood, T. Niemann, D.J. Lager, and R.E. Buller An abundance of p53 null mutations in ovarian carcinoma Oncogene 13 1996 117 123
90. M. Schuyer, S.C. Henzen-Logmans, and M.E. van der Burg High prevalence of codon 213Arg→Stop mutations of the TP53 gene in human ovarian cancer in the southwestern part of The Netherlands Int J Cancer 76 1998 299 303
91. T. Oishi, J. Kigawa, Y. Minagawa, M. Shimada, M. Takahashi, and N. Terakawa Alteration of telomerase activity associated with development and extension of epithelial ovarian cancer Obstet Gynecol 91 1998 568 571
92. M.F. Kohler, B.J. Kerns, P.A. Humphrey, J.R. Marks, R.C. Bast Jr., and A. Berchuck Mutation and overexpression of p53 in early-stage epithelial ovarian cancer Obstet Gynecol 81 1993 643 650
93. J.R. Marks, A.M. Davidoff, and B.J. Kerns Overexpression and mutation of p53 in epithelial ovarian cancer Cancer Res 1991 51
94. B.N. Ames, and L.S. Gold Too many rodent carcinogens: mitogenesis increases mutagenesis Science 249 1990 970 971
95. A.S. Whittemore, R. Harris, J. Itnyre, and J. Halpern Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. I. Methods. Collaborative Ovarian Cancer Group Am J Epidemiol 136 1992 1175 1183
96. C.H. Holschneider, and J.S. Berek Ovarian cancer: epidemiology, biology, and prognostic factors Semin Surg Oncol 19 2000 3 10
97. S.L. Stewart, T.D. Querec, B.N. Gruver, B. O'Hare, J.S. Babb, and C. Patriotis Gonadotropin and steroid hormones stimulate proliferation of the rat ovarian surface epithelium J Cell Physiol 198 2004 119 124
98. R.M. Wenham, J.M. Lancaster, and A. Berchuck Molecular aspects of ovarian cancer Best Pract Res Clin Obstet Gynaecol 16 2002 483 497
99. L.C. Hartmann, K.C. Podratz, and G.L. Keeney Prognostic significance of p53 immunostaining in epithelial ovarian cancer J Clin Oncol 12 1994 64 69
100. E. Sheridan, P. Silcocks, J. Smith, B.W. Hancock, and M.H. Goyns p53 mutation in a series of epithelial ovarian cancers from the UK, and its prognostic significance Eur J Cancer 30A 1994 1701 1704
101. A.G. van der Zee, H. Hollema, and A.J. Suurmeijer Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas J Clin Oncol 13 1995 70 78
102. L.A. Allan, M.K. Campbell, and B.J. Milner The significance of p53 mutation and over-expression in ovarian cancer prognosis Int J Gynecol Cancer 6 1996 483 490
103. M. Baekelandt, G.B. Kristensen, J.M. Nesland, C.G. Trope, and R. Holm Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer J Clin Oncol 17 1999 2061
104. G. Ferrandina, A. Fagotti, and M.G. Salerno p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer Br J Cancer 81 1999 733 740
105. Y. Mano, Y. Kikuchi, and K. Yamamoto Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer Eur J Cancer 35 1999 1214 1219
106. B.A. Goff, J.A. Ries, L.P. Els, M.D. Coltrera, and A.M. Gown Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure Gynecol Oncol 70 1998 378 385
107. S. Laframboise, W. Chapman, J. McLaughlin, and I.L. Andrulis p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance Cancer J 6 2000 302 308
108. K. Niwa, M. Itoh, and T. Murase Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance Br J Cancer 1994 70
109. B. Smith-Sorensen, J. Kaern, R. Holm, A. Dorum, C. Trope, and A.L. Borresen-Dale Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status Br J Cancer 1998 78
110. M.S. Shahin, J.H. Hughes, A.K. Sood, and R.E. Buller The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma Cancer 89 2000 2006 2017
111. A. Reles, W.H. Wen, and A. Schmider Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer Clin Cancer Res 2001 7
112. S. Fallows, J. Price, R.J. Atkinson, P.G. Johnston, I. Hickey, and S.E. Russell p53 mutation does not affect prognosis in ovarian epithelial malignancies J Pathol 194 2001 68 75
113. M. Schuyer, M.E. van der Burg, and S.C. Henzen-Logmans Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2 Br J Cancer 85 2001 1359 1367
114. L.M. Kmet, L.S. Cook, and A.M. Magliocco A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors Cancer 97 2003 389 404
115. R.W. Johnstone, A.A. Ruefli, and S.W. Lowe Apoptosis: a link between cancer genetics and chemotherapy Cell 108 2002 153 164
116. J. Kigawa, S. Sato, and M. Shimada p53 gene status and chemosensitivity in ovarian cancer Hum Cell 14 2001 165 171
117. F. Buttitta, A. Marchetti, and A. Gadducci p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study Br J Cancer 75 1997 230 235
118. A. Di Leo, E. Bajetta, and L. Biganzoli An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis Eur J Cancer 31A 1995 2248 2254
119. B. Breyer, W. Jiang, and H. Cheng Adenoviral vector-mediated gene transfer for human gene therapy Current Gene Therapy 1 2001 149 162
120. A. Kanerva, G.V. Mikheeva, and V. Krasnykh Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells Clin Cancer Res: An Off J Am Assoc Cancer Res 8 2002 275 280
121. I. Dmitriev, V. Krasnykh, and C.R. Miller An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism J Virol 72 1998 9706 9713
122. E. Casado, J. Gomez-Navarro, and M. Yamamoto Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications Clin Cancer Res: An Off J Am Assoc Cancer Res 7 2001 2496 2504
123. Y.T. Tai, T. Strobel, D. Kufe, and S.A. Cannistra In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene Cancer Res 1999 59
124. C.J. Ring, P. Blouin, L.A. Martin, H.C. Hurst, and N.R. Lemoine Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes to drive tumour-selective expression of a prodrug activating enzyme Gene Ther. 4 1997 1045 1052
125. K. Ichige, L. Perey, C.A. Vogel, F. Buchegger, and D. Kufe Expression of the DF3-P epitope in human ovarian carcinomas Clin Cancer Res: An Off J Am Assoc Cancer Res 1 1995 565 571
126. E. Casado, D.M. Nettelbeck, and J. Gomez-Navarro Transcriptional targeting for ovarian cancer gene therapy Gynecol Oncol. 82 2001 229 237
127. O.K. Glebov, K.E. McKenzie, C.A. White, and S. Sukumar Frequent p53 gene mutations and novel alleles in familial breast cancer Cancer Res. 54 1994 3703 3709
128. T. Crook, L.A. Brooks, and S. Crossland p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours Oncogene 17 1998 1681 1689
129. H. Sobol, D. Stoppa-Lyonnet, and B. Bressac-de Paillerets BRCA1-p53 relationship in heriditary breast cancer Int J Oncol 10 1997 349 353
130. K.A. Phillips, K. Nichol, and H. Ozcelik Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations J Natl Cancer Inst 91 1999 469 473
131. E. Rhei, F. Bogomolniy, and M.G. Federici Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers Cancer Res 58 1998 3193 3196
132. B. Schlichtholz, B. Bouchind'homme, and S. Pages p53 mutations in BRCA1-associated familial breast cancer Lancet 352 1998 622
133. S.P. Hussain, and C.C. Harris Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes Cancer Res 58 1998 4023 4037
134. M. Schuyer, and E.M. Berns Is TP53 dysfunction required for BRCA1-associated carcinogenesis? Mol Cell Endocrinol 155 1999 143 152
135. I. Irminger-Finger, W.C. Leung, and J. Li Identification of BARD1 as mediator between proapototic stress and p53-dependent apoptosis Moll Cell 8 2001 1255 1266
136. I. Irminger-Finger, J.V. Soriano, and G. Vaudan In vitro repression of Brca1-associated RING domain gene, Bard1, induces phenotypic changes in mammary epithelial cells J Cell Biol 143 1998 1329 1339